Synthego, a supplier of CRISPR services, has entered a strategic licensing agreement with AstraZeneca granting Synthego a global license to manufacture and distribute AstraZeneca’s CRISPR gene editing enzyme, eSpOT-ON. This state-of-the-art nuclease, developed by AstraZeneca, will be paired with Synthego’s gRNA to help enable improved health outcomes. Under the agreement, Synthego also receives exclusive commercialization rights including the right to sublicense this nuclease for ...